window.pageData = {"stock":{"_id":3000000019783,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华安健康主题混合A","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50040000","tickerId":50040000,"name":"华安基金管理有限公司"},"managers":[{"name":"刘潇","stockType":"fund_manager","stockCode":"db20582920","exchange":"fm","tickerId":1224186890}],"hotMetrics":{"fss":{"stockId":3000000019783,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.7087,"f_ind_h_s_r":0.2913,"f_h_a":182,"f_h_s_a":59897,"last_data_date":"2025-06-29T16:00:00.000Z","f_ind_h_s_r_c_hy":0.10660000000000003,"f_ins_h_s_r_c_hy":-0.10660000000000003,"f_ind_h_s_r_c_1y":-0.7087,"f_ins_h_s_r_c_1y":0.7087},"fpr":{"stockId":3000000019783,"type":"fpr","f_p_r_fys_ssc":8961,"f_p_r_fys_ssrp":0.8056919642857143,"f_p_r_m1_ssc":9300,"f_p_r_m1_ssrp":0.7685772663727283,"f_p_r_m3_ssc":9150,"f_p_r_m3_ssrp":0.7190949830582577,"f_p_r_m6_ssc":8940,"f_p_r_m6_ssrp":0.8568072491330126,"f_p_r_y1_ssc":8410,"f_p_r_y1_ssrp":0.8810797954572482,"f_cagr_p_r_fs_ssc":9241,"f_cagr_p_r_fs_ssrp":0.3588744588744589,"f_p_r_y2_ssc":7796,"f_p_r_y2_ssrp":0.568697883258499},"fp":{"stockId":3000000019783,"type":"fp","f_cagr_p_r_fs":0.08664648402760022,"f_p_r_d1":0.0012540999421184473,"f_p_r_m1":-0.059981544140264575,"f_p_r_m3":-0.015463917525773252,"f_p_r_m6":-0.10289153089681502,"f_p_r_fys":-0.06999391357273288,"f_p_r_y1":-0.023564182442686876,"last_data_date":"2026-06-25T16:00:00.000Z","f_p_r_y2":0.2750599770522584,"f_i_d":"2024-01-25T16:00:00.000Z"},"ff":{"stockId":3000000019783,"type":"ff","f_m_f_r":0.012,"f_c_f_r":0.002,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2024-12-16T16:00:00.000Z","f_c_f":112653,"f_m_a_c_f":788573,"f_m_f":675920,"f_c_fr":0.002,"f_fr_d":"2025-12-15T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000019783,"type":"f_nlacan","f_nv_d":"2026-06-25T16:00:00.000Z","f_nv":1.2224,"f_nv_cr":-0.014511447920025788},"f_as":{"stockId":3000000019783,"type":"f_as","f_tas":15144019.3944,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000019784,"name":"华安健康主题混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"019784","tickerId":19784,"shortName":"华安健康主题混合C","currency":"CNY","__csrcFundId":13485,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-01-04T00:32:27.492Z","inceptionDate":"2024-01-25T16:00:00.000Z","fundCollectionId":4000050040000,"pinyin":"hajkzthhxzqtzjj","followedNum":0}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":1000000000006990,"holdings":7000,"marketCap":2843099,"netValueRatio":0.0768,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":688331,"holdings":16868,"marketCap":2172092,"netValueRatio":0.0587,"quarterlyChange":0.6553541586322154,"stock":{"name":"荣昌生物","exchange":"sh","stockType":"company","stockCode":"688331","tickerId":688331}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":603259,"holdings":21200,"marketCap":2079720,"netValueRatio":0.0562,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":688266,"holdings":16118,"marketCap":1592458,"netValueRatio":0.043,"quarterlyChange":0.06580366774541457,"stock":{"stockCode":"688266","tickerId":688266,"exchange":"sh","stockType":"company","name":"泽璟制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":2422,"holdings":36500,"marketCap":1266185,"netValueRatio":0.0342,"quarterlyChange":0.1819420783645651,"stock":{"stockCode":"002422","exchange":"sz","stockType":"company","tickerId":2422,"name":"科伦药业"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":1000000000001530,"holdings":62500,"marketCap":1249374,"netValueRatio":0.0337,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":1000000000002096,"holdings":109000,"marketCap":1222267,"netValueRatio":0.033,"quarterlyChange":0.06098579782790292,"stock":{"stockType":"company","exchange":"hk","stockCode":"02096","tickerId":2096,"name":"先声药业"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":688428,"holdings":44710,"marketCap":1208064,"netValueRatio":0.0326,"quarterlyChange":0.31676413255360547,"stock":{"name":"诺诚健华","exchange":"sh","stockType":"company","stockCode":"688428","tickerId":688428}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":1000000000002162,"holdings":21500,"marketCap":1152293,"netValueRatio":0.0311,"quarterlyChange":0.1356407857811035,"stock":{"stockType":"company","exchange":"hk","stockCode":"02162","tickerId":2162,"name":"康诺亚-B"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockId":1000000000009926,"holdings":10000,"marketCap":1149600,"netValueRatio":0.031,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}}],"bondHoldings":[{"_id":"69e8fb651398d79843003732","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000019783,"stockCode":"019773","stockName":"25国债08","holdings":7000,"marketCap":709292,"netValueRatio":0.0192,"lastUpdated":"2026-04-22T16:46:29.761Z"}],"lastFsMetrics":{"latestTurnoverRate":6.117112190450667,"latestTurnoverRateDate":"2025-06-29T16:00:00.000Z"}},"list":[{"_id":"69e8ec361398d79843fe9b93","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000019783,"sao":"2026 年作为 “十五五” 规划的开局之年，中国经济发展锚定稳中求进、提质增效的核心取向，坚持以进促稳、先立后破，将高质量发展作为首要任务，坚定推动经济实现质的有效提升和量的合理增长，以发展的确定性应对内外环境的不确定性。中央经济工作会议明确，稳增长是底线目标，结构升级是战略目标。宏观政策将强化逆周期与跨周期调节，实施更加积极的财政政策与适度宽松的货币政策，发挥存量与增量政策的集成效应，全力护航经济平稳开局与长远升级。　　生物科技创新是新质生产力的代表，作为新兴产业与未来产业，产业扶持政策加码，鼓励国产创新药、创新器械、创新诊断研发、产业化、出海、使用政策逐步落地，商业医保扶持力度加大，也推动国内渗透率快速提升，生物科技公司在全球新分子交易方面大放异彩，中国科技重估带动春季行情。创新药、创新器械、创新诊断国际化也进入开花结果阶段，创新药LICENCE-OUT金额创历史新高，全球新分子交易中中国公司占比预计将提升到40%以上，中国公司在双抗、ADC、细胞治疗等领域的竞争力全球领先。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求高增长、附加值较高、竞争格局较好、供应链国产替代加速的环节，抵御技术创新、上游成本上升、集采规则、地缘政治带来供应链安全的风险，选择配置内生成长性突出、确定性高、估值合理的子板块与公司。　　看好刚需诊疗端的复苏，创新药、创新器械关注竞争格局较好的大适应症产品，ADC、双抗、小核酸、PROTAC、细胞治疗等创新能力提升，进入全球第一梯队，走向全球市场，肿瘤、代谢、阿尔兹海默、自免、肾病、慢阻肺等疾病仍然有大量未被满足的临床需求，驱动行业创新，为更好的人类健康与生活质量提供解决方案。　　医疗设备与耗材行业，国产替代率的提升，出海带来新的市场空间；　　医药行业融资创历史新高，CRO公司是创新产业链卖水人，发挥全球CRDMO的产业优势，有望受益行业景气度的提升。","lastUpdated":"2026-04-22T15:41:42.571Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1475384","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387bd","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000019783,"sao":"2025年四季度，国内经济复苏，扩内需、促销费、加大改革开放和高质量增长成为未来经济的发展方向。降息周期，市场流动性改善趋势明显，有利于权益资产，科技引领新经济，中国科技资产重估继续。　　医药板块过去五年处于研发高投入期，行业逐步进入收获硕果的阶段。2023年以来中国生物科技公司出海加速，抢占全球生物医药技术高地，2025年来新分子交易已经占全球交易额的40%以上，医药板块估值处于历史较低分位，医疗保健作为必选消费行业，需求具备韧性。生物科技创新是新质生产力的代表，产业扶持政策加码，鼓励国产创新药、创新器械、创新诊断研发、产业化、出海、使用政策逐步落地，医保扶持力度加大也推动国内渗透率快速提升。创新药、创新器械、创新诊断国际化也进入开花结果阶段，中国公司在双抗、ADC、细胞治疗等领域的竞争力全球领先。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求高增长、附加值较高、竞争格局较好、供应链国产替代加速的环节，抵御技术创新、上游成本上升、集采规则、地缘政治带来供应链安全的风险，选择配置内生成长性突出、确定性高、估值合理的子板块与公司；　　看好刚需诊疗端的复苏，创新药、创新器械关注竞争格局较好的大适应症产品，ADC、双抗、小核酸、PROTAC、TCE、细胞治疗等创新能力提升，进入全球第一梯队，走向全球市场，肿瘤、阿尔兹海默、自免、代谢、肾病、慢阻肺等疾病仍然有大量未被满足的临床需求，驱动行业创新，为更好的人类健康与生活质量提供解决方案；　　医疗设备与耗材行业，国产替代率的提升，出海带来新的市场空间；　　随着全球生物科技行业融资的回暖，CRO行业也迎来底部回升，进入景气提升周期；　　AI+医疗等行业应用与AGENT进入应用商业化的拐点，值得关注；　　受益消费升级的互联网医疗、医疗服务、药房板块，经历洗牌，优质民营龙头公司，有望恢复高增长。","lastUpdated":"2026-03-09T14:03:16.194Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1458585","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387bc","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000019783,"sao":"2025年三季度，市场流动性充裕，美元进入降息周期，市场仍然维持流动性宽松趋势。医药板块过去五六年处于研发高投入期，行业逐步进入收获硕果的阶段。2023年以来中国生物科技公司出海加速，抢占全球生物医药技术高地，2025年来新分子交易已经占全球交易额的40%以上，医药板块估值处于历史中位数，医疗保健作为必选消费行业，需求具备韧性。　　投资策略上，我们聚焦医药健康产业链上需求高增长、附加值较高、竞争格局较好、供应链国产替代加速的环节，抵御技术创新、上游成本上升、集采规则、地缘政治带来供应链安全的风险，选择配置内生成长性突出、确定性高、估值合理的子板块与公司。　　展望2026年十五五开局之年，医疗健康需求是人类命运共同体需要攻克的共同方向，即使遇到贸易保护等变化，行业需求与全球精细分工趋势不会变化，我们仍然看好中国生物科技在全球的持续竞争力。","lastUpdated":"2026-03-09T14:03:16.191Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1375468","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387bb","date":"2025-06-29T16:00:00.000Z","stockId":3000000019783,"sao":"2025年国内经济复苏，扩内需、促销费、加大改革开放和高质量增长成为未来经济的发展方向。　　医药板块过去五年处于研发高投入期，行业逐步进入收获硕果的阶段。2023年以来中国生物科技公司出海加速，抢占全球生物医药技术高地，2025年来新分子交易已经占全球交易额的40%以上，医药板块估值处于历史较低分位，医疗保健作为必选消费行业，需求具备韧性。　　生物科技创新是新质生产力的代表，产业扶持政策加码，鼓励国产创新药、创新器械、创新诊断研发、产业化、出海、使用政策逐步落地，医保扶持力度加大也推动国内渗透率快速提升。创新药、创新器械、创新诊断国际化也进入开花结果阶段，创新药LICENCE-OUT金额创历史新高，全球新分子交易中中国公司占比预计将提升到40%以上，中国公司在双抗、ADC、细胞治疗等领域的竞争力全球领先。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求高增长、附加值较高、竞争格局较好、供应链国产替代加速的环节，抵御技术创新、上游成本上升、集采规则、地缘政治带来供应链安全的风险，选择配置内生成长性突出、确定性高、估值合理的子板块与公司；　　看好刚需诊疗端的复苏，创新药、创新器械关注竞争格局较好的大适应症产品，ADC、双抗、小核酸、PROTAC、细胞治疗等创新能力提升，进入全球第一梯队，走向全球市场，肿瘤、阿尔兹海默、自免、肾病、慢阻肺等疾病仍然有大量未被满足的临床需求，驱动行业创新，为更好的人类健康与生活质量提供解决方案；　　医疗设备与耗材行业，国产替代率的提升，出海带来新的市场空间；　　受益消费升级的医疗服务、药房板块，经历洗牌，优质民营龙头公司，有望恢复高增长。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.188Z","mo":"展望2025年下半年，海外高利率环境有所改善，国内宽信用空间打开，科技引领高质量增长，创新药、创新器械进入研发收获期，出海竞争力不断提升，海外授权等催化，提升价值上限。人口老龄化带来的银发经济空间巨大，肿瘤、代谢、心脑血管、精神神经、眼科、骨科、康复等领域迎来市场加速扩容。基因细胞治疗、多肽、ADC、多抗、TCE、小核酸、基因编辑等新技术的发展，在诊疗、泛消费领域的应用拓展更大的空间。","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1349093","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387ba","date":"2025-03-30T16:00:00.000Z","stockId":3000000019783,"sao":"2025年国内经济复苏，扩内需、促销费、加大改革开放和高质量增长成为未来经济的发展方向。　　医药板块估值处于历史较低分位，医疗保健作为必选消费行业，需求具备韧性。　　生物科技创新是新质生产力的代表，产业扶持政策加码，鼓励国产创新药、创新器械、创新诊断研发、产业化、出海、使用政策逐步落地，医保扶持力度加大也推动国内渗透率快速提升。创新药、创新器械、创新诊断国际化也进入开花结果阶段，创新药LICENCE-OUT金额创历史新高，全球新分子交易中中国公司占比预计将提升到40%以上，中国公司在双抗、ADC、细胞治疗等领域的竞争力全球领先。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求高增长、附加值较高、竞争格局较好、供应链国产替代加速的环节，抵御技术创新、上游成本上升、集采规则、地缘政治带来供应链安全的风险，选择配置内生成长性突出、确定性高、估值合理的子板块与公司；　　看好刚需诊疗端的复苏，创新药、创新器械关注竞争格局较好的大适应症产品，ADC、双抗、小核酸、PROTAC等创新能力提升，进入全球第一梯队，走向全球市场，肿瘤、阿尔兹海默、自免、肾病、慢阻肺等疾病仍然有大量未被满足的临床需求，驱动行业创新，为更好的人类健康与生活质量提供解决方案；　　AI大模型在医疗行业应用也进入加速发展阶段，院内、院外，诊前诊中诊后场景应用不断出现，对于医院流程运营、药品研发、辅助诊断、健康管理、精准营销等方面应用，为医药行业研发、制造、营销提效。　　疾病预防意识提升，疫苗、血液制品等板块的需求加速增长，新产品上市带来新的增长点；　　医疗设备与耗材行业，国产替代率的提升，出海带来新的市场空间；　　受益消费升级的医疗服务、药房板块，经历了疫情、产业政策的洗牌，优质民营龙头公司，有望恢复高增长；　　中医中药板块扶持政策力度加大，中药创新药、OTC等板块有望兑现加速增长。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.184Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1273070","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387b9","date":"2024-12-30T16:00:00.000Z","stockId":3000000019783,"sao":"基金配置策略上，我们集中到代表行业先进生产力与符合产业发展趋势的方向，包括创新药、创新器械、CXO等，降低了仿制药、消费医疗等相关行业的配置。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.179Z","mo":"随着国内金融、经济、财政一揽子增量政策的推出，资本市场与国内经济迎来复苏，制造业出口趋势向好，稳出口、扩内需，高质量、安全发展成为未来的发展方向。医药行业迎来政策暖风，全链条鼓励医药行业创新，人工智能等新技术的应用也有望提升行业研发效率，商业医保活水有望带来行业新的发展机遇。 　　医药板块估值处于历史较低分位，行业高质量发展趋势明显，研发费用比例大幅提升，全球竞争力有显著提升。医疗保健作为必选消费行业，人口加速老龄化带来医疗健康需求未来十年保持10%以上增长，刚需属性带来行业确定性扩容空间，骨科、代谢、阿尔兹海默等相关行业患病率也将出现提升，叠加国内医疗器械、生物技术、创新药等行业出口市场份额提升，医疗保健仍然是朝阳行业。　　产业趋势上来看，国产创新药、AI+创新器械诊断、国际化进入开花结果阶段，创新药LINCENCE-OUT金额创历史新高，医保扶持力度加大也推动国内渗透率快速提升。中医药行业遇产业政策春风，创新加速，高质量发展，集中度提升趋势明显。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求刚性、竞争格局较好、附加值较高、供应链国产替代加速的环节，抵御支付力趋弱、集采竞价、地缘政治带来供应链安全的风险，选择配置内生成长确定性高、估值较低的子板块与公司，享受企业成长的同时，关注企业的分红价值的提升：　　关注诊疗端的刚需成长，门诊端创新药、创新器械有望迎来放量，关注竞争格局较好的大适应症产品，ADC、双抗、PROTAC、细胞治疗等创新能力进去第一梯队，走向全球市场；　　高端医疗设备与AI、机器人技术结合的创新也上新台阶，辅助诊断、数字医疗等迎来新的发展机会。　　全球医药板块融资恢复增长，CXO行业有望迎来复苏，科学世界大模型的发展也有望提升医药研发的效率。","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1254535","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387b8","date":"2024-09-29T16:00:00.000Z","stockId":3000000019783,"sao":"2024年三季度，随着国内金融、经济、财政一揽子增量政策的推出，资本市场与国内经济迎来复苏，制造业出口趋势向好，稳出口、扩内需，高质量、安全发展成为未来的发展方向。　　医药板块估值处于历史较低分位，行业高质量发展趋势明显，研发费用比例大幅提升，全球竞争力有显著提升。医疗保健作为必选消费行业，人口加速老龄化带来医疗健康需求未来十年保持10%以上增长，刚需属性带来行业确定性扩容空间，骨科、代谢、阿尔兹海默等相关行业患病率也将出现提升，叠加国内医疗器械、生物技术、创新药等行业出口市场份额提升，医疗保健仍然是朝阳行业。　　产业趋势上来看，国产创新药、创新器械、创新诊断国际化也进入开花结果阶段，创新药LINCENCE-OUT金额创历史新高，医保扶持力度加大也推动国内渗透率快速提升。中医药行业遇产业政策春风，创新加速，高质量发展，集中度提升趋势明显。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求刚性、竞争格局较好、附加值较高、供应链国产替代加速的环节，抵御支付力趋弱、集采竞价、地缘政治带来供应链安全的风险，选择配置内生成长确定性高、估值较低的子板块与公司，享受企业成长的同时，关注企业的分红价值的提升：　　关注诊疗端的刚需成长，门诊端创新药、创新器械有望迎来放量，关注竞争格局较好的大适应症产品，ADC、双抗、PROTAC、细胞治疗等创新能力进去第一梯队，走向全球市场；　　中成药板块扶持政策力度加大，中药OTC、慢病用药等板块有望兑现稳定增长，基药政策有望带来新的增长契机；　　高端医疗设备、医疗耗材国产替代趋势仍在，在门诊量恢复的背景下，行业将迎来复苏。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.176Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1174512","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387b7","date":"2024-06-29T16:00:00.000Z","stockId":3000000019783,"sao":"2024年上半年，国内经济复苏，制造业出口趋势向好，稳出口、扩内需，高质量、安全发展成为未来的发展战略。　　医药板块估值处于历史较低分位，行业高质量发展趋势明显，研发费用比例大幅提升，全球竞争力有显著提升。医疗保健作为必选消费行业，人口加速老龄化带来医疗健康需求未来十年保持10%以上增长，刚需属性带来行业确定性扩容空间，骨科、代谢、阿尔兹海默等相关行业患病率也将出现提升，叠加国内医疗器械、生物技术、创新药等行业出口市场份额提升，医疗保健仍然是朝阳行业。　　产业趋势上来看，国产创新药、创新器械、创新诊断国际化也进入开花结果阶段，创新药LINCENCE-OUT金额创历史新高，医保扶持力度加大也推动国内渗透率快速提升。中医药行业遇产业政策春风，创新加速，高质量发展，集中度提升趋势明显。　　从医药基金配置策略上，我们更加聚焦医药健康产业链上需求刚性、竞争格局较好、附加值较高、供应链国产替代加速的环节，抵御支付力趋弱、集采竞价、地缘政治带来供应链安全的风险，选择配置内生成长确定性高、估值较低的子板块与公司，享受企业成长的同时，关注企业的分红价值的提升：　　关注诊疗端的刚需成长，门诊端创新药、创新器械有望迎来放量，关注竞争格局较好的大适应症产品，ADC、双抗、PROTAC、细胞治疗等创新能力进去第一梯队，走向全球市场；　　中成药板块扶持政策力度加大，中药OTC、慢病用药等板块有望兑现稳定增长，基药政策有望带来新的增长契机；　　高端医疗设备、医疗耗材国产替代趋势仍在，行业将迎来复苏。","declarationDate":"2024-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.174Z","mo":"展望2024年下半年，全球经济与金融市场可能仍有动荡，国内必选消费仍然是内需稳定器，国产替代加速与举国创新体制，中国科技企业有望迎来发展黄金期。　　医药行业兼具消费刚需与科技创新双重属性，经历了较长时间的估值调整，医药板块的绝对估值处于历史较低水平，在经济偏弱的背景下，医药板块的成长确定性也凸显，进入较好的配置区间。　　医院诊疗端复苏，择期手术与专科诊疗端复苏明确，人口老龄化带来的骨科、心血管、糖尿病、眼科、神经系统等行业药品、器械耗材进入需求加速增长期，中长线具备较好的投资机会；　　BIOTECH板块：全链路支持创新药发展政策推出，融资触底回升，大领域差异化，看重更快、更优、全球化的创新，创新药、器械竞争格局优化，跨越了从0到1孵化期进入1到N的商业化成长期的公司，有望进入价值的高速增长期；　　中药：医保支持力度加大，政策扶持创新，中药创新药有望迎来经营拐点；　　高端设备与耗材国产替代加速，医疗设备、检测仍然维持高景气，出口市场也有新的拓展。","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1152239","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed3247fea5b3eb05387b6","date":"2024-03-30T16:00:00.000Z","stockId":3000000019783,"sao":"2024年国内经济复苏，消费、投资企稳回升，制造业出口趋势向好，稳出口、扩内需，加大改革开放和高质量增长成为未来经济的发展方向。海外高利率环境有所改善，但是通胀压力仍在，对于企业的自身造血能力要求提升，内需之外拓展海外市场的能力也很重要，出海也对企业提出了更高的全球化的要求。　　我们的投资策略聚焦受益消费升级与科技进步的行业，以全球竞争的视角，选择大市场、高壁垒的赛道，关注具备长期竞争优势的公司，在合适的估值参与，长期持有，分享市场扩容、企业价值增长的红利。　　建仓策略上我们选取确定性与稳定性的标的作为底仓，在成长中精选竞争力突出，经营稳健，估值有安全边际的标的，增强组合的抗风险能力的基础上，追求高质量的成长。","declarationDate":"2024-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T14:03:16.170Z","fund":{"_id":3000000019783,"__csrcFundId":13485,"stockCode":"019783","masterFundShortName":"华安健康主题混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19783,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T02:30:06.399Z","status":"normal","exchange":"jj","shortName":"华安健康主题混合(019783)","name":"华安健康主题混合型证券投资基金","fundCollectionId":4000050040000,"inceptionDate":"2024-01-25T16:00:00.000Z","setUpAssetScale":5980621.81,"setUpDate":"2024-01-23T16:00:00.000Z","setUpShares":5980621.81,"pinyin":"hajkzthhxzqtzjj","followedNum":1,"managers":[{"stockCode":"db20582920","stockType":"fund_manager","exchange":"fm","tickerId":1224186890,"name":"刘潇"}]},"announcement":{"linkText":"华安健康主题混合型证券投资基金2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1073244","linkType":"PDF","source":"csrc_pdf"}}]}